The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available in the market for lowering cholesterol levels. Some of the statins used in the US include Atorvastatin (Lipitor), Lovastatin (Altoprev), Pitavastatin (Livalo, Zypitamag), Pravastatin (Pravachol), Rosuvastatin (Crestor, Ezallor), and Simvastatin (Zocor).

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/hyperlipidemia-drug-market

Further, according to the American Heart Association (AHA), historical data shows 79.8% of adults who were at least 40 years old use of statins for lowering cholesterol from 2002 to 2013 studies. Such an extensive rise in the number of statinusers is driving the growth of the hyperlipidemia drug market. However, increasing side effects associated withstatin drugs is expected to hinder the growth of the statin drug market. Statins drugs have side effects and some patients are unable to bear it. For instance, atorvastatin and rosuvastatin are high-intensity statins which cause rare side effects like new-onset diabetes and muscle symptoms.

A Full Report of Global Hyperlipidemia Drug Market is Available at: https://www.omrglobal.com/industry-reports/hyperlipidemia-drug-market

Hence, the demand for non-statin drugs is expected to contribute to hyperlipidemia drug market growth in the near future. In 2020, the FDA has approved two non-statin drugs after a long period of the last 2 decades. For instance, in February 2020, The FDA approved the first non-statin oral medication for high cholesterol commercialized in the US and around the world. The drug, bempedoic acid, is the first in a new class of drugs to treat low-density-lipoprotein cholesterol.

Further, in February 2020, Esperion Therapeutics Inc received FDA approval for its Nexletol, a new type of cholesterol-lowering drug. This drug will help people manage their high cholesterol and reduce the risk of heart diseases. Further, other non-statin drugs for lowering cholesterol include PCSK9-targeting drugs such as Amgen’s Repatha (evolocumab), Sanofi’s Praluent (alirocumab) and inclisiran, developed by Alnylam Pharmaceuticals and The Medicines Company and currently under FDA review.

Global Hyperlipidemia Drug Market Segmentation

By Drug Class

HMG-CoA Reductase Inhibitors (Statins)
PCSK9 Inhibitors
Cholesterol Absorption Inhibitors
Fabric Acid Derivatives (Fibrates)
Niacin (Nicotinic Acid)
Bile Acid Sequestrants (BAS)
Combination Therapy and Compliance
Others

Global Hyperlipidemia Drug Market Segmentation by region

North America

United States
Canada

Europe

UK
Germany
Italy
Spain
France
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of the Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hyperlipidemia-drug-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404